Psychedelics Becoming Valuable Alternatives to Conventional Mental Health Treatments

Stock Information for Mydecine Innovations Group Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Mydecine Innovations Group Inc

Mydecine Innovations Group Provides Update on European Operations
Mydecine Announces Change of Auditor
Mydecine Innovations Group Announces Plans to Spin Out of its [U.S.] Cannabis Assets
Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain
Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation (API) at the University of Alberta
Mydecine Innovations Group Announces Filing of a Provisional Patent for Mindleap's Mental Health Technology
Mydecine Innovations Group Announces Closing of $17,250,000 Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option
Mydecine Innovations Group Files Final Prospectus in Connection with Bought Deal Offering of Units

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.